[{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evopoint Biosciences \/ Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd.","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Shanghai Dingyue Biotechnology Co., LTD | Beijing Jiyingjia Medical Laboratory | Shanghai Jinghan Biological Technology Co., Ltd."},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Evopoint Biosciences \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"AmMax Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evopoint Biosciences \/ AmMax Bio","highestDevelopmentStatusID":"4","companyTruncated":"Evopoint Biosciences \/ AmMax Bio"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"METiS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||SOS1","graph1":"Oncology","graph2":"Discovery","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evopoint Biosciences \/ Evopoint Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evopoint Biosciences \/ Evopoint Biosciences"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Rectal","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Astellas Pharma"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Staphylococcus Beta-lactamase (Stap-coc blaZ)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Staphylococcus Beta-lactamase (Stap-coc blaZ)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Imipenem","moa":"||Staphylococcus Beta-lactamase (Stap-coc blaZ)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evopoint Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Staphylococcus Beta-lactamase (Stap-coc blaZ)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evopoint Biosciences \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Evopoint Biosciences
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
